A 72-year-old man with chronic kidney disease (baseline creatinine 2.5 mg/dL, eGFR 22 mL/min/1.73m²) is admitted with acute decompensated heart failure. He is started on intravenous furosemide 80 mg twice daily. On day 3, his serum creatinine rises to 3.8 mg/dL, urine output is 0.5 mL/kg/hr, and serum potassium is 6.2 mEq/L. Urinalysis shows no casts or proteinuria. Renal ultrasound is normal with no obstruction. What is the most appropriate immediate next step in management?

Explanation

## Clinical Scenario Analysis This patient has **cardiorenal syndrome (CRS)** — a combination of acute kidney injury superimposed on chronic kidney disease, triggered by aggressive diuresis in the setting of heart failure. The absence of casts and proteinuria, normal ultrasound, and preserved urine output (not yet anuric) suggest **prerenal AKI** from volume depletion, not intrinsic renal disease. ## Why This Is the Correct Approach **Key Point:** In cardiorenal syndrome, the kidney injury is driven by inadequate renal perfusion pressure despite systemic volume overload. Aggressive diuresis worsens this paradox. The immediate goal is to: 1. **De-escalate diuretics** to restore renal perfusion 2. **Assess true volume status** (FENa, urine osmolality, clinical exam) 3. **Treat life-threatening hyperkalemia** (K⁺ 6.2 is symptomatic risk) 4. **Reassess cardiac status** without worsening renal function **High-Yield:** Cardiorenal Syndrome Classification: | Type | Mechanism | Trigger | Management | |------|-----------|---------|-------------| | **CRS-1** | Acute decompensation → ↓ renal perfusion | Acute HF exacerbation | ↓ Diuretics, inotropes, vasodilators | | **CRS-2** | Chronic cardiorenal dysfunction | Chronic low output | ACE-I, β-blockers, judicious diuretics | This patient has **CRS-1**. Continuing aggressive diuresis will worsen the vicious cycle: ↓ renal perfusion → ↑ Cr → ↑ RAAS activation → ↑ systemic vasoconstriction → ↓ cardiac output. **Clinical Pearl:** In CRS-1, the paradox is that the patient *looks* volume-overloaded (HF) but is *functionally* volume-depleted at the renal level. Diuretics help the lungs but hurt the kidneys. The solution is **gentler diuresis** with **inotropic or vasodilatory support** (dobutamine, milrinone, or low-dose dopamine) to improve renal perfusion without increasing afterload. ## Hyperkalemia Management (K⁺ 6.2 mEq/L) **Immediate actions:** - **Calcium gluconate 10%** 10 mL IV (stabilize myocardium) — within 1–3 min - **Insulin 10 units + dextrose 25 g IV** (shift K⁺ intracellularly) — within 10–20 min - **Sodium bicarbonate 50 mEq IV** (if metabolic acidosis present) - **Loop diuretic** (if volume allows) or **cation-exchange resin** (sodium polystyrene sulfonate) - **Avoid ACE-I / ARB temporarily** until K⁺ < 5.5 and renal function stabilizes **Mnemonic — CRS Management: "DIAL"** - **D**iuretics → reduce dose (not stop entirely) - **I**notropes / vasodilators → add to improve renal perfusion - **A**ddress hyperkalemia → calcium, insulin, bicarb - **L**oop back to reassess (daily labs, urine output, Cr trend) ## Why Not the Other Options? | Option | Problem | |--------|----------| | Continue furosemide + add second diuretic | Worsens prerenal AKI; ignores hyperkalemia; perpetuates cardiorenal cycle | | Stop diuretics + restrict fluid + emergency dialysis | Dialysis premature (Cr 3.8 in CKD baseline, not yet anuric); fluid restriction harmful in CRS-1 | | Switch to nitro + hold all diuretics | Loses diuretic benefit for pulmonary edema; nitro alone insufficient for HF; no renal-specific strategy | [cite:Harrison 21e Ch 279, Ch 233]